Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals |
| gptkbp:activities |
gptkb:drug
|
| gptkbp:approves |
gptkb:legislation
gptkb:2002 gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:brand |
gptkb:Lexapro
gptkb:Escitalopram_oxalate gptkb:Cipralex |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
MAO inhibitors
hypersensitivity to escitalopram |
| gptkbp:developed_by |
gptkb:Lundbeck
Forest Laboratories |
| gptkbp:dosage_form |
oral tablet
oral solution |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Escitalopram
|
| gptkbp:ingredients |
C20 H21 F N2 O
|
| gptkbp:interacts_with |
gptkb:beer
NSAI Ds other SSR Is |
| gptkbp:is_atype_of |
N06 A B10
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
generalized anxiety disorder
major depressive disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
27 to 32 hours
|
| gptkbp:metabolism |
liver
|
| gptkbp:requires |
FDA label
|
| gptkbp:side_effect |
anxiety
dizziness fatigue headache nausea sleep disturbances vomiting diarrhea restlessness withdrawal symptoms insomnia constipation dry mouth weight gain sweating blurred vision apathy tremors sexual dysfunction agitation increased risk of bleeding serotonin syndrome increased sweating emotional blunting sexual side effects |
| gptkbp:type_of |
219861-08-2
|